Variants of STAT3 Linked to T-cell Lymphoma Induce a Regulatory Phenotype
Overview
Revise to specify the implications of STAT3 mutations in T-cell malignancies beyond anti-inflammatory responses.
Background
STAT3 signaling is crucial for T cell function, influencing processes such as metabolism, apoptosis, and cytokine production. Mutations in STAT3 are prevalent in T-cell cancers, particularly T-cell large granular lymphocytic leukemias, where they are associated with a gain-of-function phenotype. Understanding these mutations is essential for developing targeted therapies and improving patient outcomes.
Data Highlights
No numerical data available in the source material.
Key Findings
STAT3 mutations, particularly Y640F and N647I, exhibit gain-of-function phenotypes.
Y640F has more extensive transcriptome-wide effects compared to N647I.
Both variants invoke a T regulatory 1 (Tr1) gene program, characterized by IL-10 expression.
Tr1 skewing is observed in both mouse models and human T-cell malignancies.
These mutations may help transformed T cells evade immune responses.
Clinical Implications
The findings suggest that targeting STAT3 signaling could be a viable therapeutic strategy in T-cell malignancies. Understanding the regulatory effects of STAT3 mutations may inform treatment approaches and improve management of T-cell cancers.
Conclusion
The study enhances the understanding of how STAT3 mutations contribute to T-cell malignancies, emphasizing the need for targeted therapies that address these oncogenic pathways.
Patients diagnosed with metastatic breast cancer and non–small cell lung cancer had longer survival compared to national benchmarks when treated in independent community oncology practices, according ...
The investigational KRAS G12D inhibitor zoldonrasib had a favorable safety profile and induced antitumor activity in some patients with KRAS G12D–mutated non–small cell lung cancer (NSCLC) who were pr...
